Artelo Biosciences Announces Data From Preclinical Trial In Neuropathic Pain From Spinal Cord Injury Shows Lowered Mechanical Hypersensitivi
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced positive new data from a preclinical study in n